CY1105638T1 - Xρηση του μεταβολιτη της βαλσαρτανης για την αναστoλη της αιμοπεταλιακης συσσωρευσης - Google Patents
Xρηση του μεταβολιτη της βαλσαρτανης για την αναστoλη της αιμοπεταλιακης συσσωρευσηςInfo
- Publication number
- CY1105638T1 CY1105638T1 CY20061101409T CY061101409T CY1105638T1 CY 1105638 T1 CY1105638 T1 CY 1105638T1 CY 20061101409 T CY20061101409 T CY 20061101409T CY 061101409 T CY061101409 T CY 061101409T CY 1105638 T1 CY1105638 T1 CY 1105638T1
- Authority
- CY
- Cyprus
- Prior art keywords
- platelet aggregation
- valsartan
- inhibiting platelet
- metabolite
- ischemic
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 title abstract 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 title abstract 3
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical class C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 title abstract 2
- 208000032382 Ischaemic stroke Diseases 0.000 abstract 2
- 208000011580 syndromic disease Diseases 0.000 abstract 2
- ICSQZMPILLPFKC-XLDIYJRPSA-N 4-Hydroxyvalsartan Chemical class C1=CC(CN(C(=O)CCC(O)C)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=NN1 ICSQZMPILLPFKC-XLDIYJRPSA-N 0.000 abstract 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 abstract 1
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 206010003178 Arterial thrombosis Diseases 0.000 abstract 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 abstract 1
- 206010008479 Chest Pain Diseases 0.000 abstract 1
- 206010051055 Deep vein thrombosis Diseases 0.000 abstract 1
- 208000005189 Embolism Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 208000018262 Peripheral vascular disease Diseases 0.000 abstract 1
- 206010047249 Venous thrombosis Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 206010000891 acute myocardial infarction Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000002815 pulmonary hypertension Diseases 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 230000001732 thrombotic effect Effects 0.000 abstract 1
- 230000001052 transient effect Effects 0.000 abstract 1
- 229960004699 valsartan Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38037302P | 2002-05-14 | 2002-05-14 | |
| US39501402P | 2002-07-11 | 2002-07-11 | |
| PCT/EP2003/004997 WO2003094915A1 (en) | 2002-05-14 | 2003-05-13 | Use of valsartan ot its metabolite to inhibit platelet aggregation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1105638T1 true CY1105638T1 (el) | 2010-12-22 |
Family
ID=29423705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20061101409T CY1105638T1 (el) | 2002-05-14 | 2006-09-28 | Xρηση του μεταβολιτη της βαλσαρτανης για την αναστoλη της αιμοπεταλιακης συσσωρευσης |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US20050197372A1 (https=) |
| EP (1) | EP1505965B1 (https=) |
| JP (1) | JP4467427B2 (https=) |
| KR (1) | KR101005367B1 (https=) |
| CN (1) | CN100408035C (https=) |
| AT (1) | ATE334677T1 (https=) |
| AU (1) | AU2003267447B8 (https=) |
| BR (1) | BR0310018A (https=) |
| CA (1) | CA2482541A1 (https=) |
| CY (1) | CY1105638T1 (https=) |
| DE (1) | DE60307265T2 (https=) |
| DK (1) | DK1505965T3 (https=) |
| ES (1) | ES2268403T3 (https=) |
| IL (2) | IL164774A0 (https=) |
| MX (1) | MXPA04011282A (https=) |
| NO (1) | NO20045245L (https=) |
| NZ (1) | NZ536295A (https=) |
| PL (1) | PL371728A1 (https=) |
| PT (1) | PT1505965E (https=) |
| RU (1) | RU2334512C2 (https=) |
| TW (1) | TWI299663B (https=) |
| WO (1) | WO2003094915A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040265238A1 (en) * | 2003-06-27 | 2004-12-30 | Imtiaz Chaudry | Inhalable formulations for treating pulmonary hypertension and methods of using same |
| TW200523257A (en) * | 2003-09-26 | 2005-07-16 | Novartis Ag | Use of organic compounds |
| AR057882A1 (es) | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
| AR068814A1 (es) * | 2007-08-29 | 2009-12-09 | Orion Corp | Composicion farmaceutica que comprende levosimendan y un inhibidor de la enzima conversina de la angiotensina (ace), y uso |
| RU2410104C1 (ru) * | 2009-07-10 | 2011-01-27 | Учреждение Российской академии медицинских наук Научный центр неврологии РАМН | СПОСОБ СНИЖЕНИЯ АГРЕГАЦИОННОЙ АКТИВНОСТИ ТРОМБОЦИТОВ in vitro |
| US10478404B2 (en) | 2014-01-24 | 2019-11-19 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Materials, methods and devices for altering cell reactivity |
| CN110078640B (zh) * | 2019-03-29 | 2022-04-05 | 浙江美诺华药物化学有限公司 | 一种缬沙坦中间体的合成方法 |
| CN111643557B (zh) * | 2020-05-26 | 2022-02-22 | 四川省骨科医院 | 一种防治下肢深静脉血栓后遗症期的药物组合物及其制备方法和用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE312198T1 (de) * | 1993-04-05 | 2005-12-15 | Univ Utah Res Found | Diagnose und behandlung von supravalvular aortic stenosis |
| US6395728B2 (en) * | 1999-07-08 | 2002-05-28 | Novartis Ag | Method of treatment and pharmaceutical composition |
| CA2379666C (en) * | 1999-07-21 | 2009-10-13 | Takeda Chemical Industries, Ltd. | Agent for preventing recurrence of cerebrovascular disorder and agent for ameliorating troubles following cerebrovascular disorder and inhibiting progress thereof |
| AU2001267404A1 (en) * | 2000-05-04 | 2001-11-12 | Ipf Pharmaceuticals Gmbh | Novel compounds for the treatment of inflammatory and cardiovascular diseases |
| NZ522953A (en) * | 2000-06-22 | 2005-10-28 | Novartis Ag | Tablet containing valsartan, microcrystalline cellulose, crospovidone, colloidal anhydrous silica/colloidal silicon dioxide and magnesium stearate |
-
2003
- 2003-05-12 TW TW092112854A patent/TWI299663B/zh not_active IP Right Cessation
- 2003-05-13 IL IL16477403A patent/IL164774A0/xx unknown
- 2003-05-13 AU AU2003267447A patent/AU2003267447B8/en not_active Ceased
- 2003-05-13 MX MXPA04011282A patent/MXPA04011282A/es active IP Right Grant
- 2003-05-13 WO PCT/EP2003/004997 patent/WO2003094915A1/en not_active Ceased
- 2003-05-13 DK DK03749892T patent/DK1505965T3/da active
- 2003-05-13 ES ES03749892T patent/ES2268403T3/es not_active Expired - Lifetime
- 2003-05-13 CA CA002482541A patent/CA2482541A1/en not_active Abandoned
- 2003-05-13 CN CNB03810864XA patent/CN100408035C/zh not_active Expired - Fee Related
- 2003-05-13 EP EP03749892A patent/EP1505965B1/en not_active Expired - Lifetime
- 2003-05-13 RU RU2004136583/15A patent/RU2334512C2/ru not_active IP Right Cessation
- 2003-05-13 BR BR0310018-9A patent/BR0310018A/pt not_active IP Right Cessation
- 2003-05-13 US US10/514,299 patent/US20050197372A1/en not_active Abandoned
- 2003-05-13 KR KR1020047018282A patent/KR101005367B1/ko not_active Expired - Fee Related
- 2003-05-13 AT AT03749892T patent/ATE334677T1/de active
- 2003-05-13 PT PT03749892T patent/PT1505965E/pt unknown
- 2003-05-13 DE DE60307265T patent/DE60307265T2/de not_active Expired - Lifetime
- 2003-05-13 NZ NZ536295A patent/NZ536295A/en not_active IP Right Cessation
- 2003-05-13 PL PL03371728A patent/PL371728A1/xx unknown
- 2003-05-13 JP JP2004503001A patent/JP4467427B2/ja not_active Expired - Lifetime
-
2004
- 2004-10-21 IL IL164774A patent/IL164774A/en not_active IP Right Cessation
- 2004-11-30 NO NO20045245A patent/NO20045245L/no not_active Application Discontinuation
-
2006
- 2006-09-28 CY CY20061101409T patent/CY1105638T1/el unknown
-
2009
- 2009-02-02 US US12/363,926 patent/US20100048654A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003267447A1 (en) | 2003-11-11 |
| KR20050000532A (ko) | 2005-01-05 |
| JP4467427B2 (ja) | 2010-05-26 |
| ATE334677T1 (de) | 2006-08-15 |
| DE60307265T2 (de) | 2007-07-19 |
| CN1652774A (zh) | 2005-08-10 |
| HK1074395A1 (en) | 2005-11-11 |
| PL371728A1 (en) | 2005-06-27 |
| TW200410686A (en) | 2004-07-01 |
| AU2003267447B8 (en) | 2009-08-06 |
| NZ536295A (en) | 2006-12-22 |
| US20100048654A1 (en) | 2010-02-25 |
| JP2005529913A (ja) | 2005-10-06 |
| PT1505965E (pt) | 2006-11-30 |
| MXPA04011282A (es) | 2005-01-25 |
| AU2003267447B2 (en) | 2006-11-02 |
| WO2003094915A1 (en) | 2003-11-20 |
| BR0310018A (pt) | 2005-02-15 |
| CA2482541A1 (en) | 2003-11-20 |
| KR101005367B1 (ko) | 2010-12-30 |
| IL164774A0 (en) | 2005-12-18 |
| DK1505965T3 (da) | 2006-11-13 |
| EP1505965A1 (en) | 2005-02-16 |
| RU2334512C2 (ru) | 2008-09-27 |
| RU2004136583A (ru) | 2005-09-10 |
| IL164774A (en) | 2010-04-29 |
| US20050197372A1 (en) | 2005-09-08 |
| ES2268403T3 (es) | 2007-03-16 |
| DE60307265D1 (de) | 2006-09-14 |
| CN100408035C (zh) | 2008-08-06 |
| TWI299663B (en) | 2008-08-11 |
| EP1505965B1 (en) | 2006-08-02 |
| NO20045245L (no) | 2004-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1105638T1 (el) | Xρηση του μεταβολιτη της βαλσαρτανης για την αναστoλη της αιμοπεταλιακης συσσωρευσης | |
| CO6430463A2 (es) | Activadores de guanilato ciclasa solubles | |
| ECSP10010017A (es) | Activadores de guanilato ciclasas solubles | |
| NZ716245A (en) | Fused benzoxazepinones as ion channel modulators | |
| NO20080761L (no) | Acykliske Ikur inhibitorer | |
| DE602004020120D1 (de) | Nachweis von diastolischer herzinsuffizienz | |
| CY1108817T1 (el) | Ανοσολογικη θεραπεια για την αντιμετωπιση της αθηροσκληρωσης | |
| CO5601002A2 (es) | Inhibidores de la acc | |
| LTPA2015023I1 (lt) | Ospemifeno bioaktyvumo padidinimo būdas | |
| CY1112058T1 (el) | Χρηση των χιτοζανων για την αυξηση του βαθμου αναπτυξης των νυχιων | |
| CY1112173T1 (el) | Η χρηση της cilobradine ή των φαρμακευτικα αποδεκτων αλατων αυτης για την θεραπεια ή την προληψη της καρδιακης ανεπαρκειας | |
| JP2006525972A5 (https=) | ||
| EP4058147A4 (en) | NOVEL ANTIMALARIAL AGENT CONTAINING A HETEROCYCLIC COMPOUND | |
| PE20110293A1 (es) | Combinacion de dosis fija en la forma de una tableta de una sola capa que comprende alisquireno y amlodipina | |
| ATE506943T1 (de) | Matrixkontrolliertes transdermales system mit salzen der ace-hemmer-dicarbonsäuren | |
| PY0639426A (es) | Asociación de un inhibidor de la corriente sinusal if, la ivabradina, y de un inhibidor de la enzima de conversión de la angiotensina | |
| CY1105403T1 (el) | Χρηση της ακετυλο-l-καρνιτινης σε συνδυασμο με τη βιοτινη για τη θepαπεια ασθενων με ινσουλινο-ανθεκτικο σακχαρωδη διαβητη τυπου 2 | |
| BRPI0517964A (pt) | derivados de dicarboxamida | |
| JP2007514769A5 (https=) | ||
| Güvenç et al. | A novel explanation for the cause of atrial fibrillation seen in atherosclerotic coronary artery disease:“downstream inflammation” hypothesis | |
| RU2020132055A (ru) | Кнопка | |
| RU2021107731A (ru) | Моноадамант-2-иламинопропиловый эфир янтарной кислоты, обладающий актопротекторной (термопротекторной) активностью | |
| CL2021001484S1 (es) | Bidón. (divisional solicitud 202000904) | |
| CL2025001765S1 (es) | Reloj pulsera. | |
| RU2015145911A (ru) | Способ оценки риска развития неблагоприятных сердечно-сосудистых событий у больных ишемической болезнью сердца с сахарным диабетом 2 типа после стентирования коронарных артерий |